| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8445661 | European Journal of Cancer | 2012 | 9 Pages |
Abstract
Treatment for stage II and III LR or IR WT is successful in a neoadjuvant setting as advised by the SIOP. Stage, tumour volume and blastemal type histology are the most important prognostic factors.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Norbert Graf, Harm van Tinteren, Christophe Bergeron, François Pein, Marry M. van den Heuvel-Eibrink, Bengt Sandstedt, Jens-Peter Schenk, Jan Godzinski, Foppe Oldenburger, Rhoikos Furtwängler, Jan de Kraker,